IMMUNOLOGICAL CHARACTERIZATION OF ANTIGENIC DOMAINS ON HUMAN IL-2 RECEPTOR-BETA SUBUNIT - EPITOPE-FUNCTION RELATIONSHIPS

被引:7
作者
FRANCOIS, C
SOREL, M
CHEREL, M
BRAILLY, H
MINVIELLE, S
BLANCHARD, D
JACQUES, Y
机构
[1] INSERM,U211,F-44035 NANTES 01,FRANCE
[2] CHU NANTES,INST BIOL,F-44035 NANTES 01,FRANCE
[3] CTR REG TRANSFUS SANGUINE,F-4401 NANTES 01,FRANCE
[4] IMMUNOTECH SA,F-13288 MARSEILLE 09,FRANCE
关键词
BINDING STOICHIOMETRIES; ELISA; INTERACTION; SOLUBLE RECEPTOR; PROLIFERATION; T CELLS;
D O I
10.1093/intimm/7.8.1173
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Five mAb directed at the IL-2R beta chain were analyzed for their binding and functional properties. They define three epitopes on a recombinant soluble beta chain or on the beta chain expressed at the surface of YT-2C2 cells. Epitope 1 (A41 and 6E8 mAb) is part of the IL-2 binding domain, whereas epitope 2 (CF1 and 6E10 mAb) is not involved in IL-2 binding. Epitope 3 (6B5 mAb) also partly overlaps the IL-2 binding domain but does not overlap epitopes 1 and 2. None of the mAb can by themselves inhibit IL-2 induced proliferation of a human activated T cell clone. Only epitope 1 mAb can synergize with an anti-alpha chain mAb to inhibit this proliferation. Using epitope 1 and 2 mAb as well as a purified, recombinant form of the IL-2R beta chain extracellular domain, an ELISA-based immunoassay was set up which allows the quantitative determination of soluble and detergent solubilized IL-2R beta chains. Epitopes 1 and 2 are in non-competitive interaction: the binding of a mAb to one epitope decreases the affinity of a mAb for the second epitope. Epitope 2 mAb have binding stoichiometries (-16,000 sites/cell) which are -80% higher than that of epitope 1 mAb and IL-2 itself (-9000 sites/cell), Upon binding of epitope 2 mAb, the stoichiometries of epitope 1 mAb and IL-2 are increased to reach the stoichiometry of epitope 2 mAb, A molecular model is proposed in which the IL-2R beta chain exists in two different states on YT-2C2 cells: one associated with the intermediate-affinity IL-2R ply complex, the other being part of a receptor structure which is not accessible to epitope 1 mAb and IL-2.
引用
收藏
页码:1173 / 1181
页数:9
相关论文
共 28 条
[1]  
Minami Y., Kono T., Miyasaki T., Taniguchi T., The IL-2 receptor complex: Its structure, function and target genes. Annu, Rev. Immunol, 11, (1993)
[2]  
Nikaido T., Shimizu A., Ishida N., Sabe H., Teshigawara K., Maeda M., Uchiyama T., Yodoi J., Honjo T., Molecular cloning of cDNA encoding human interleukin-2 receptor, Nature, 311, (1984)
[3]  
Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., Munakata H., Nakamura M., Sugamura K., Cloning of the gamma chain of the human IL-2 receptor, Science, 257, (1992)
[4]  
Hatakeyama M., Tsudo M., Minamoto S., Kono T., Doi T., Miyata T., Miyasaka M., Taniguchi T., Interleukin-2 receptor beta chain gene: Generation of three receptor forms by cloned human alpha and beta chain cDNA’s, Science, 244, (1989)
[5]  
Nakamura Y., Russel S.M., Mess S.A., Friedmann M., Erdos M., Francois C., Jacques Y., Adelstein S., Leonard W.J., Fleterodimerization of the IL-2 receptor p and y chain cytoplasmic domains is required for signaling, Nature, 369, (1994)
[6]  
Leonard W.J., Depper J.M., Uchiyama T., Smith K.A., Waldmann T.A., Greene W.C., A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor
[7]  
partial purification of the receptor, Nature, 300, (1982)
[8]  
Le Mauff B., Gascan H., Olive O., Moreau J.F., Mawas C., Soulillou J.P., Jacques Y., Parameters of interaction of a novel monoclonal antibody (33B3.1) with the human IL-2 receptors: Interrelations between 33B3.1, anti-Tac and IL-2 binding sites, Human Immunol, 19, (1987)
[9]  
Fujii M., Sugamura K., Nakai D.I., Tanaka Y., Tozawa Y., Hinuma Y., High and low-affinity receptors: Distinctive effects of monoclonal antibodies, J. Immunol, 137, (1986)
[10]  
Rubin L.A., Kurmann C.C., Biddison W.E., Goldmann N.D., Nelson D.L., A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin 2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac, Hybridoma, 4, (1985)